ᓄᓇᕗᑦ ᒪᓂᒻᒪᐃᔪᑦ ᐱᖓᔪᖓᓐᓂᒃ ᑲᐱᔭᐅᔾᔪᑎᒃᓴᒥᒃ ᐃᓄᖕᓄᑦ ᐋᓐᓂᐊᖃᖅᑐᓄᑦ

ᓄᓇᕗᒥᑦ ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᑦ ᑐᓴᖅᑎᑦᑎᓚᐅᕐᑐᑦ ᐅᒃᑑᐱᕆ 5-ᒥ ᐃᓚᖏ ᓄᓇᕗᒥᐅᑕᑦ ᐱᖓᔪᖓᓐᓂ ᑲᐱᔭᐅᔪᓐᓇᕐᓂᖏᓐᓂᒃ ᓴᐳᔾᔭᐅᓯᒪᔾᔪᑎᒃᓴᒥ ᓄᕙᒡᔪᐊᕐᓇᖅ-19-ᒧ.

ᐃᓱᒪᓕᐊᕆᔭᐅᓯᒪᖕᒪᑦ ᑲᓇᑕᒥ ᖃᐅᔨᓴᒪᔨᒋᔭᐅᔪᑦ ᑲᑎᒪᔨᓄᑦ ᑲᐱᔭᐅᔾᔪᑎᐅᕙᒃᑐᓄᑦ ᒪᑯᐊ ᐃᓅᓕᓴᐅᑎᓄᑦ ᓱᖁᓯᓗᐊᖃᑦᑕᕈᓐᓃᕐᓯᒪᔪᑦ ᑲᐱᔭᐅᒃᑲᓐᓂᖁᔭᐅᓪᓗᑎᒃ ᑖᔅᓱᒥᖓ.

ᑲᑎᒪᔨᑦ ᐃᓱᒪᓕᐅᕆᓚᐅᕐᒪᑕ ᑖᔅᓱᒥᖓ ᓯᑎᐱᕆ 10-ᒥ. ᐊᓯᖏᑦᑕᐅᖅ ᑲᓇᑕᒦᑦᑐᑦ ᐱᖓᔪᖓᓐᓂ ᑲᐳᓯᔾᔪᑎᒃᓴᖃᕐᒥᔪᑦ ᑕᒪᒃᑯᓄᖓ ᐋᓐᓂᐊᓕᕐᓴᕋᐃᓐᓂᕐᓴᐅᕙᒃᑐᓄ, ᐅᑯᓇᓂ ᓄᓇᑦᓯᐊᖅ, ᔫᑳᓐ, ᐋᓐᑎᐅᕆᐅ ᐊᒻᒪ ᐋᐴᑕᒥ.

ᑐᓴᒐᒃᓴᓕᐊᕆᔭᐅᔪᓂᒃ ᐅᑯᓇᙵᑦ ᐋᓐᓂᐊᖃᕐᓇᙱᑦᑐᓕᕆᔨᒃᑯᓐᓂᒃ ᓇᓗᓇᐃᔭᐃᓯᒪᖕᒪᑕ ᖃᓄᐃᑦᑐᓂᒃ ᐋᓐᓂᐊᖑᕙᒃᑐᓂᒃ ᒪᑯᓄᖓ 12-ᓂ ᐅᑭᐅᓕᖕᓂ ᐅᖓᑖᓄᓪᓗ.

ᐅᑯᓂᖓ ᐃᓚᖃᕐᑐᑦ:

• ᒫᓐᓇ ᐱᓕᕆᐊᖑᑲᑕᒃᖢᓂ ᐋᓐᓂᐊᖃᕐᓂᕐᒧᑦ ᕿᓕᕐᓯᓇᒃᑯ ᐅᕝᕙᓘᓐᓃᑦ ᑳᓐᓱᖑᔭᑦᑐᓂᒃ
• ᐊᓯᐊᓂᒃ ᑭᓱᑖᕐᓯᒪᓂᕐᒧᑦ (ᓲᕐᓗ ᑎᖑᒃ) ᓇᓗᓇᐃᒃᑯᑎᖃᕐᓗᑎ ᐊᒻᒪᓗ ᑖᔅᓱᒧᖓ ᑲᒪᒋᔭᐅᑲᑕᒡᓗᑎᒃ
• ᐃᓅᓕᓴᐅᑎᒃᑯᑦ ᑲᒪᒋᔭᐅᔾᔪᑎᖃᕐᓗᑎᒃ ᒪᑯᓄᖓ ᐊᐅᓕᕐᓱᖅᑕᐅᔾᔪᑎᓄᑦ (chimeric antigen receptor (CAR)-T-cell therapy) ᐅᕝᕙᓘᓐᓃᑦ ᐊᓯᐊᓂᒃ ᑭᓱᑖᕐᓯᒪᓂᕐᒧᑦ ᑎᒥᒃᑰᕈᑎᐅᒃᑲᓐᓂᕈᓐᓇᖅᑐᓂᒃ (ᐊᕐᕌᒎᒃ ᒪᕐᕉᒃ ᐊᓂᒍᖅᑎᓪᓗᒍ ᐊᓯᐊᓂ ᐱᑖᖅᑕᐅᓚᐅᕐᓗᓂ ᐅᕝᕙᓘᓐᓃᑦ ᐊᑐᕈᓐᓇᕈᑎᒃᓴᓂᒃ)
• ᐃᓅᓕᓴᐅᑎᓂᒃ ᐊᑐᙱᓗᐊᕈᑎᖃᖅᑐᑦ, ᐆᒥᖓ ᐃᓚᖃᖅᖢᓂ DiGeorge syndrome ᐅᕝᕙᓘᓐᓃᑦ Wiskott-Aldrich syndrome
• ᖁᕝᕙᓯᖕᓂᓕᒃ 3 ᐅᕝᕙᓘᓐᓃᑦ ᐊᓴᐱᒧᑦ ᑲᒪᒋᔭᐅᙱᓐᓂᕐᒧᑦ ᐊᒻᒪᓗ ᐊᓴᐱᖃᖅᑐᑦ
• ᒫᓐᓇ ᑲᒪᒋᔭᐅᒍᕕᑦ ᒪᑯᓄᖓ immunosuppressive therapies ᐃᓚᖃᕐᓗᓂ: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 ᐊᒻᒪ CD22; high-dose systemic corticosteroids; alkylating agents; antimetabolites; or tumour necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive

“ᐅᖃᖃᑎᒋᓗᒍ ᐋᓐᓂᐊᓯᐅᖅᑎᒋᔭᐃᑦ ᑕᒪᒃᑯᓂᖓ ᐄᔭᒐᕐᓂ ᐱᖃᑦᑕᕆᐊᒃᓴᐃᑦ ᐅᕝᕙᓘᓐᓃᑦ ᐃᓕᖕᓄᑦ ᑐᕌᖓᒃᐸᑦ,” ᐅᖃᖅᓯᒪᔪᑦ ᑐᓴᒐᒃᓴᕆᔭᐅᔪᖅ.

ᐱᖓᔪᖓᓐᓂ ᑲᐱᔭᐅᔾᔪᑎ ᐊᑐᐃᓐᓇᐅᔪᖅ ᓘᑖᒥ ᐅᕝᕙᓘᓐᓃ ᐋᓐᓂᐊᓯᐅᕐᑎᒥ ᑎᑎᖃᖃᕐᓗᓂ, ᐅᖃᖅᓯᒪᔪᖅ ᑐᓴᒐᒃᓴᓕᐊᕆᔭᐅᔪᖅ.